Datasheet for ABIN1042596

anti-CYBB antibody

1 Image | 2 Publications

Go to Product page

Overview

Quantity:	0.1 mL
Target:	CYBB
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This CYBB antibody is un-conjugated
Application:	Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Immunocytochemistry (ICC)

Product Details

Immunogen:	Partially Purified human neutrophil flavocytochrome b (heparin Ultrogellectin affinity purification in Triton X-100)
Clone:	54-1
Isotype:	IgG1
Specificity:	This antibody is specific for NOX2/gp91phox 382-PKIAVDGP-389
Purification:	Protein G

Target Details

Target:	CYBB
Alternative Name:	NOX2/gp91phox (CYBB Products)

Target Details

Background:	Synonyms: CGD91-phox antibody,CYBB antibody,Cytochrome b(558) beta chain antibody,Cytochrome b-245 heavychain antibody,gp91-1 antibody,gp91-phox antibody,Heme-binding membrane glycoprotein gp91phox antibody,NADPHoxidase 2 antibody,Neutrophil cytochrome b 91 kDa polypeptide antibody,NOX2 antibody,p22 phagocyte B-cytochromeantibody,Superoxide-generating NADPH oxidase heavy chain subunit antibody
Gene ID:	21577
OMIM:	300481
UniProt:	Q01062

Application Details

Application Notes:	Optimal antibody concentration should be determined by titration, however as a guideline try,WB: Use at an assay dependent dilution. Detects a band of approximately 65 kDa (predicted molecular weight: 65 kDa).ICC/IF: Use a concentration of 1 µg/mL.IHC-P: Use a concentration of 5 µg/mL. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol
Comment:	Myeloma, fusion partners: SP2/0
Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	1 mg/mL
Buffer:	Purified antibody containing PBS 0.1 % sodium azide
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Publications

Product cited in:	Baek, Eling: "Changes in gene expression contribute to cancer prevention by COX inhibitors." in: **Progress in lipid research**, Vol. 45, Issue 1, pp. 1-16, (2006) (PubMed).



Image 1.